Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
The Journal of Sexual Medicine|January 13, 2016
Resveratrol Protects and Restores Endothelium-Dependent Relaxation in Hypercholesterolemic Rabbit Corpus CavernosumNergiz Murat, Peyda Korhan, Onur Kizer, et al.
International Journal of Clinical Practice|April 2, 2021
Urinary microbiota; Which non-ınvasive urine collection method should we use?Muhammed Selcuk Ozer, Huseyin Alperen Yildiz, Canet Incir, et al.
International Journal of Clinical Practice|August 19, 2020
Easily accessible, up-to-date and standardised training model in Urology: E-Learning Residency training programme (ERTP)Volkan Sen, Huseyin Eren, Ilke Onur Kazaz, et al.
Urology|February 6, 2007
Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunctionKaan Bal, Mehmet Oder, Ali S Sahin, et al.
International Journal of Clinical Practice|April 19, 2017
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)Marcus J Drake, Scott MacDiarmid, Christopher R Chapple, et al.
Urologia Internationalis|September 22, 2024
Comparison of Tissue and Urine Microbiota in Male, Intervention Naive Patients with and without Non-Invasive Bladder CancerMuhammed S Ozer, Canet Incir, Huseyin A Yildiz, et al.
Asian Journal of Andrology|July 3, 2013
Erectile function and late-onset hypogonadism symptoms related to lower urinary tract symptom severity in elderly menOzan Bozkurt, Deniz Bolat, Omer Demir, et al.
The Lancet. Oncology|October 20, 2022
Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b studyAxel S Merseburger, Gerhardt Attard, Lennart Åström, et al.
International Journal of Clinical Practice|April 18, 2021
How did the COVID-19 pandemic affect audience's attitudes in webinars?Yiloren Tanidir, Fatih Gokalp, Nebil Akdogan, et al.
The Lancet. Oncology|May 13, 2024
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trialAndrea Necchi, Mathieu Roumiguié, Ashish M Kamat, et al.
Pageof 6